Seattle Genetics Inc. (SGEN)

60.65
0.66 1.10
NASDAQ : Health Technology
Prev Close 59.99
Open 59.74
Day Low/High 58.51 / 60.98
52 Wk Low/High 47.75 / 84.37
Volume 734.17K
Avg Volume 1.13M
Exchange NASDAQ
Shares Outstanding 160.15M
Market Cap 9.94B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Seattle Genetics Highlights Multiple Data Sets Evaluating The Combination Of ADCETRIS® (Brentuximab Vedotin) And Opdivo® (Nivolumab) At ASH Annual Meeting

Seattle Genetics Highlights Multiple Data Sets Evaluating The Combination Of ADCETRIS® (Brentuximab Vedotin) And Opdivo® (Nivolumab) At ASH Annual Meeting

Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted data from three ongoing clinical trials evaluating the combination of ADCETRIS (brentuximab vedotin) and Opdivo (nivolumab) at the 60 th American Society of Hematology (ASH) Annual Meeting and...

Seattle Genetics To Webcast Investor And Analyst Event At American Society Of Hematology Annual Meeting

Seattle Genetics To Webcast Investor And Analyst Event At American Society Of Hematology Annual Meeting

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the company will webcast an investor and analyst event on Monday, December 3, 2018 during the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, Calif.

Seattle Genetics Announces FDA Approval Of ADCETRIS® (Brentuximab Vedotin) In Combination With Chemotherapy For Adults With Previously Untreated Systemic Anaplastic Large Cell Lymphoma Or Other CD30-Expressing Peripheral T-Cell Lymphomas

Seattle Genetics Announces FDA Approval Of ADCETRIS® (Brentuximab Vedotin) In Combination With Chemotherapy For Adults With Previously Untreated Systemic Anaplastic Large Cell Lymphoma Or Other CD30-Expressing Peripheral T-Cell Lymphomas

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced a new approval for ADCETRIS ® (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) from the U.

FDA Grants Breakthrough Therapy Designation To ADCETRIS® (Brentuximab Vedotin) For Frontline Peripheral T-Cell Lymphomas

FDA Grants Breakthrough Therapy Designation To ADCETRIS® (Brentuximab Vedotin) For Frontline Peripheral T-Cell Lymphomas

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.

Seattle Genetics Initiates Phase 1 Clinical Trial Of SEA-BCMA For Patients With Relapsed Or Refractory Multiple Myeloma

Seattle Genetics Initiates Phase 1 Clinical Trial Of SEA-BCMA For Patients With Relapsed Or Refractory Multiple Myeloma

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today dosing of the first patient in a phase 1 clinical trial evaluating the safety and tolerability of SEA-BCMA for patients with relapsed or refractory multiple myeloma (MM).

Seattle Genetics To Present At The Credit Suisse 27th Annual Healthcare Conference

Seattle Genetics To Present At The Credit Suisse 27th Annual Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Credit Suisse 27 th Annual Healthcare Conference on Tuesday, November 13, 2018 at 2:15 p.

Seattle Genetics Submits Supplemental Biologics License Application For ADCETRIS® (Brentuximab Vedotin) In Frontline Treatment Of CD30-Expressing Peripheral T-Cell Lymphomas

Seattle Genetics Submits Supplemental Biologics License Application For ADCETRIS® (Brentuximab Vedotin) In Frontline Treatment Of CD30-Expressing Peripheral T-Cell Lymphomas

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.

Seattle Genetics Announces More Than 30 Presentations At ASH 2018 Highlighting Progress With Broad ADCETRIS® (Brentuximab Vedotin) Development Program

Seattle Genetics Announces More Than 30 Presentations At ASH 2018 Highlighting Progress With Broad ADCETRIS® (Brentuximab Vedotin) Development Program

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that 31 abstracts featuring data from the broad ADCETRIS (brentuximab vedotin) development program have been accepted for presentation at the 60 th American Society of Hematology (ASH) Annual Meeting...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXS, EXPE, FNHC, SAVE Downgrades: BC, BLDR, CDE, CLB, CLS, CMG, COR, CRI, FBIZ, FBM, RXN, SGEN, THRM, TLRA, VC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Seattle Genetics Announces Multiple Data Presentations Evaluating ADCETRIS® (Brentuximab Vedotin) In Patients With Hodgkin Lymphoma At ISHL 2018

Seattle Genetics Announces Multiple Data Presentations Evaluating ADCETRIS® (Brentuximab Vedotin) In Patients With Hodgkin Lymphoma At ISHL 2018

Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted multiple presentations evaluating ADCETRIS (brentuximab vedotin) across a broad range of Hodgkin lymphoma (HL) settings at the 11 th International Symposium on Hodgkin Lymphoma (ISHL) taking place in...

Seattle Genetics Reports Third Quarter 2018 Financial Results

Seattle Genetics Reports Third Quarter 2018 Financial Results

Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the third quarter and nine months ended September 30, 2018.

Genmab And Seattle Genetics Announce Tisotumab Vedotin Data To Be Presented At ESMO 2018 Congress

Genmab And Seattle Genetics Announce Tisotumab Vedotin Data To Be Presented At ESMO 2018 Congress

Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that updated clinical data from the innovaTV 201 Phase II study evaluating tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer will be...

Seattle Genetics To Host Conference Call And Webcast Discussion Of Third Quarter Financial Results On October 25, 2018

Seattle Genetics To Host Conference Call And Webcast Discussion Of Third Quarter Financial Results On October 25, 2018

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter financial results on Thursday, October 25, 2018 after the close of financial markets.

Seattle Genetics And Takeda Announce Positive Results From Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) In Frontline CD30-Expressing Peripheral T-Cell Lymphoma

Seattle Genetics And Takeda Announce Positive Results From Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) In Frontline CD30-Expressing Peripheral T-Cell Lymphoma

Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited ( TSE:4502) announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval In Japan For Frontline Hodgkin Lymphoma

Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval In Japan For Frontline Hodgkin Lymphoma

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination...

Seattle Genetics To Present At The Morgan Stanley Global Healthcare Conference

Seattle Genetics To Present At The Morgan Stanley Global Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Morgan Stanley Global Healthcare Conference on Thursday, September 13, 2018 at 2:05 p.

Seattle Genetics Reports Second Quarter 2018 Financial Results

Seattle Genetics Reports Second Quarter 2018 Financial Results

Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the second quarter and six months ended June 30, 2018.

Seattle Genetics Announces First Patient Dosed In Phase 2 InnovaTV 207 Trial Evaluating Tisotumab Vedotin In Multiple Solid Tumors

Seattle Genetics Announces First Patient Dosed In Phase 2 InnovaTV 207 Trial Evaluating Tisotumab Vedotin In Multiple Solid Tumors

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the phase 2 innovaTV 207 clinical trial evaluating the activity, safety and tolerability of tisotumab vedotin as monotherapy in selected solid tumors with high Tissue...

Cisco Systems, Herbalife, Under Armour: 'Mad Money' Lightning Round

Cisco Systems, Herbalife, Under Armour: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Cisco Systems, Herbalife, Under Armour, Axon Enterprise, Seattle Genetics, Roku, Procter & Gamble, Bank of Nova Scotia.

Tariffs Fueling Rotation: Cramer's 'Mad Money' Recap (Wednesday 7/11/18)

Tariffs Fueling Rotation: Cramer's 'Mad Money' Recap (Wednesday 7/11/18)

Jim Cramer says tariff news doesn't really rattle the markets, it moves money from one sector to another. Here's his strategy for navigating this volatility.

Seattle Genetics Announces Publication Of Results From Two Tucatinib Phase 1b Clinical Trials In HER2-Positive Metastatic Breast Cancer

Seattle Genetics Announces Publication Of Results From Two Tucatinib Phase 1b Clinical Trials In HER2-Positive Metastatic Breast Cancer

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that results of a phase 1b clinical trial of tucatinib in combination with standard of care agents for the treatment of patients with advanced HER2-positive (HER2+) metastatic breast cancer were...

Seattle Genetics And Astellas Announce Progress In Enfortumab Vedotin Urothelial Cancer Clinical Development Program

Seattle Genetics And Astellas Announce Progress In Enfortumab Vedotin Urothelial Cancer Clinical Development Program

-Enrollment of EV-201 Pivotal Trial Cohort Designed to Support Potential Expedited Registration Pathway in the U.S. Completed-

Seattle Genetics And Astellas Announce Progress In Enfortumab Vedotin Urothelial Cancer Clinical Development Program

Seattle Genetics And Astellas Announce Progress In Enfortumab Vedotin Urothelial Cancer Clinical Development Program

Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: APOG, LNN, LTC, MLAB, NKE, SGEN Downgrades: DIT, GMS, PDVW, WUBA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Seattle Genetics To Host Conference Call And Webcast Discussion Of Second Quarter Financial Results On July 26, 2018

Seattle Genetics To Host Conference Call And Webcast Discussion Of Second Quarter Financial Results On July 26, 2018

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter financial results on Thursday, July 26, 2018 after the close of financial markets.

Seattle Genetics Announces First Patient Dosed In Phase 2 Trial Of Tisotumab Vedotin For Women With Recurrent Or Metastatic Cervical Cancer

Seattle Genetics Announces First Patient Dosed In Phase 2 Trial Of Tisotumab Vedotin For Women With Recurrent Or Metastatic Cervical Cancer

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the phase 2 innovaTV 204 clinical trial evaluating the efficacy, safety and tolerability of tisotumab vedotin as monotherapy for patients with recurrent and/or metastatic...

Seattle Genetics To Present At The Goldman Sachs 39th Annual Global Healthcare Conference

Seattle Genetics To Present At The Goldman Sachs 39th Annual Global Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 1:20 p.

Seattle Genetics Highlights Additional Analyses From Phase 3 ECHELON-1 Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) In Newly Diagnosed Advanced Hodgkin Lymphoma At 2018 ASCO Annual Meeting

Seattle Genetics Highlights Additional Analyses From Phase 3 ECHELON-1 Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) In Newly Diagnosed Advanced Hodgkin Lymphoma At 2018 ASCO Annual Meeting

Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted data from the phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy in newly diagnosed stage III or IV classical Hodgkin lymphoma (HL) at the 2018...

TheStreet Quant Rating: D+ (Sell)